Pfizer executives left before the negotiation! National Health Insurance Administration: No more special negotiations on Paxlovid

According to China Business News, the National Medical Insurance Administration will no longer hold special negotiations with Pfizer on Paxlovid. Relevant sources said that the National Medical Insurance Administration showed “great sincerity” in the negotiations with Pfizer, but due to the large differences between the two parties, the negotiations were not successful. The consideration of the medical insurance department is that “our country has a large population base, and the amount of medication will be very large. The medical insurance department must consider the bearing capacity of funds and society. In addition, a person familiar with the matter revealed, “Including Paxlovid, a total of 6 Pfizer drugs were included in the medical insurance on that day. negotiation. The first five were all discussed by their vice presidents. When it came time to talk about Paxlovid, the vice presidents and other executives had already left. ” | Related reading (Daily Economic News)

Han Yuan

This result is a “lose-lose”. The drug Pfizer lost the huge market in China, and domestic patients also lost the good drug Pfizer. It can only be said that Pfizer’s medical insurance bureau is very stubborn and unwilling to compromise.

However, Merck’s Molnupiravir has been approved, domestically produced Azvudine has been covered by medical insurance, and Pfizer’s P drug is said to be produced in China. In addition, the current first round of infection has basically ended, so there is no big worry.

This incident also reflects a problem, that is, although the Chinese market is large, some companies will not compromise on their pricing principles. Buying, the card is still our own neck.

Although the price of P drugs in medical insurance is not high at present, it will expire soon. Maybe at that time, ordinary people can only buy it at the original price at their own expense.

This article is reproduced from: https://www.fortunechina.com/jingxuan/26176.htm
This site is only for collection, and the copyright belongs to the original author.